Tag Archives: Leponex

Schizophrenia: Current Therapies

Etiology and Pathophysiology Schizophrenia has varied and ominous symptoms that generally begin in late adolescence or early adulthood and usually continue throughout life. The diagnostic criteria for schizophrenia have evolved over the past 20 years based on the different iterations of the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases.… Read More »

Schizophrenia: Atypical Antipsychotics

Many atypical antipsychotics are available. In addition to those reviewed in the following sections, atypical agents include perospirone (Sumitomo’s Lullan) and zotepine (Fujisawa’s Lodopin, Aventis’s Nipolept, Orion Pharma’ s Zoleptil, generics). These drugs are not discussed in detail here because their mechanisms of action are similar to those of other atypical agents, they are launched… Read More »

Schizophrenia: Serotonin-Dopamine Antagonists

Serotonin-dopamine antagonists, together with dopamine partial agonists, are considered atypical antipsychotics. serotonin-dopamine antagonists have been used for the treatment of schizophrenia since the early 1990s, and currently marketed serotonin-dopamine antagonists include Novartis’s clozapine (Clozaril/Leponex, generics), Janssen’s risperidone (Risperdal), Eli Lilly’s olanzapine (Zyprexa), AstraZeneca’s quetiapine (Seroquel), and Pfizer’s ziprasidone (Geodon/Zeldox). TABLE . Emerging Therapies in Development… Read More »

Chronic Illness: Current Therapies

The main goal of bipolar disorder drug treatment is to establish euthymia (stable mood with a persistent sense of well-being) without inducing mania or rapid cycling (i.e., four or more mood episodes in a 12-month period). For this reason, drug treatment usually consists of an agent or, more frequently, combinations of agents that exert both… Read More »